IVINGTON, N.Y., Oct. 14, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that it will release its 2013 third quarter financial results after the close of trading on Wednesday, November 6, 2013. MELA Sciences’ executives will also host a conference call that day at 4:30 PM ET to discuss the results, as well as provide a general business update.
Help employers find you! Check out all the jobs and post your resume.
